Skip to main content
. Author manuscript; available in PMC: 2014 May 1.
Published in final edited form as: Circ Heart Fail. 2013 Mar 18;6(3):572–583. doi: 10.1161/CIRCHEARTFAILURE.112.000200

Figure 6. The expression of a constitutively active FOXO3a impairs cardiac diastolic and systolic function in a rat model of early POH.

Figure 6

6-A: M-mode images two weeks after gene delivery via a cross clamp technique and AAB. 6 B-E: There were significant decreases in LV weight, IVSd, LVPWd and LV EF and significant increase in LV end systolic volume in the Ad-FX3a + AAB group, *P<0.05 vs Ad-Null + AAB and Ad-DN-FX3a + AAB, #P<0.05 vs Ad-Null. There was slight but significant decrease in LV end systolic volume and increase in LVEF in the Ad-DN-FX3 + AAB group, &P<0.05 vs Ad-Null + AAB. 6 F-I: Pressure-volume loop measurements showed significant decreases in LV maximum pressure and EF and significant increases in LVEDP in the Ad-FX3a + AAB group, *P<0.05 vs Ad-Null + AAB and Ad-DN-FX3a + AAB, #P<0.05 vs Ad-Null. There was significant decrease in LVEDP and a slight but significant increase in LVEF in the Ad-DN-FX3a + AAB group, &P<0.05 vs Ad-Null + AAB. 6-J: FOXO3a expression increased in the Ad-FX3a and Ad-DN-FX3a groups, #P<0.05 vs Ad-Null and Ad-Null + AAB. BNIP3 expression increased in the Ad-Null + AAB and in the Ad-FX3a + AAB groups, #P<0.05 vs Ad-Null and *P<0.05 vs all other groups. The delivery of Ad-DN-FX3a significantly attenuated the increase in BNIP3 expression in response to PO, &P<0.05 vs Ad-Null + AAB and Ad-FX3a + AAB.